258 related articles for article (PubMed ID: 33898313)
1. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.
Cerchione C; Romano A; Daver N; DiNardo C; Jabbour EJ; Konopleva M; Ravandi-Kashani F; Kadia T; Martelli MP; Isidori A; Martinelli G; Kantarjian H
Front Oncol; 2021; 11():639387. PubMed ID: 33898313
[TBL] [Abstract][Full Text] [Related]
2. Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.
Ragon BK; DiNardo CD
Curr Hematol Malig Rep; 2017 Dec; 12(6):537-546. PubMed ID: 29064021
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
Liu X; Gong Y
Biomark Res; 2019; 7():22. PubMed ID: 31660152
[TBL] [Abstract][Full Text] [Related]
4. IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H; Fletcher L; Traer E
Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
[TBL] [Abstract][Full Text] [Related]
5. The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia.
Zhuang X; Pei HZ; Li T; Huang J; Guo Y; Zhao Y; Yang M; Zhang D; Chang Z; Zhang Q; Yu L; He C; Zhang L; Pan Y; Chen C; Chen Y
Front Oncol; 2022; 12():931462. PubMed ID: 35814406
[TBL] [Abstract][Full Text] [Related]
6. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
Lee S; Urman A; Desai P
Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
[TBL] [Abstract][Full Text] [Related]
7. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
Becker JS; Fathi AT
Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690
[TBL] [Abstract][Full Text] [Related]
8. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Abou Dalle I; DiNardo CD
Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
[TBL] [Abstract][Full Text] [Related]
9. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.
Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
[TBL] [Abstract][Full Text] [Related]
10. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
[TBL] [Abstract][Full Text] [Related]
11. Recent advances of IDH1 mutant inhibitor in cancer therapy.
Tian W; Zhang W; Wang Y; Jin R; Wang Y; Guo H; Tang Y; Yao X
Front Pharmacol; 2022; 13():982424. PubMed ID: 36091829
[TBL] [Abstract][Full Text] [Related]
12. Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR
Olarte I; García A; Ramos C; Arratia B; Centeno F; Paredes J; Rozen E; Kassack J; Collazo J; Martínez A
Onco Targets Ther; 2019; 12():8023-8031. PubMed ID: 31632056
[TBL] [Abstract][Full Text] [Related]
13. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
[TBL] [Abstract][Full Text] [Related]
14. Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment.
Reed DR; Elsarrag RZ; Morris AL; Keng MK
Cancer Manag Res; 2019; 11():8073-8080. PubMed ID: 31564968
[TBL] [Abstract][Full Text] [Related]
15. Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.
Lachowiez C; DiNardo CD; Stein E
Cancer J; 2022 Jan-Feb 01; 28(1):21-28. PubMed ID: 35072370
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Issa GC; DiNardo CD
Blood Cancer J; 2021 Jun; 11(6):107. PubMed ID: 34083508
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review.
Tangella AV; Gajre A; Kantheti VV
Cureus; 2023 Sep; 15(9):e44802. PubMed ID: 37692182
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.
Stemer G; Rowe JM; Ofran Y
Blood Lymphat Cancer; 2021; 11():41-54. PubMed ID: 34188585
[TBL] [Abstract][Full Text] [Related]
19. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
DiNardo CD; Stein EM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
[TBL] [Abstract][Full Text] [Related]
20. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
